Donepezil Is Associated with Delayed Nursing Home Placement in Patients with Alzheimer's Disease

OBJECTIVES: To assess the relationship between donepezil treatment and time to nursing home placement (NHP) for patients with Alzheimer's disease (AD).

[1]  D. Spencer,et al.  Practice parameter: Temporal lobe and localized neocortical resections for epilepsy: Report of the Quality Standards Subcommittee of the American Academy of Neurology, in Association with the American Epilepsy Society and the American Association of Neurological Surgeons , 2003, Neurology.

[2]  S. Wisniewski,et al.  Cholinesterase inhibitor treatment alters the natural history of Alzheimer's disease , 2002, Journal of neurology, neurosurgery, and psychiatry.

[3]  N. Bosanquet,et al.  The epidemic of Alzheimer's disease. How can we manage the costs? , 2000, PharmacoEconomics.

[4]  R. Ernst,et al.  Economic research on Alzheimer disease: a review of the literature. , 1997, Alzheimer disease and associated disorders.

[5]  A. Heyman,et al.  The Consortium to Establish a Registry for Alzheimer's Disease (CERAD) , 1993, Neurology.

[6]  B. Oken.  Practice parameter: Management of dementia (an evidence-based review) , 2001, Neurology.

[7]  L. Friedhoff,et al.  The efficacy and safety of donepezil in patients with Alzheimer's disease: Results of a US multicentre, randomized, double-blind, placebo-controlled trial , 1996 .

[8]  B. Chenoweth,et al.  Dementia: the experience of family caregivers. , 1986, The Gerontologist.

[9]  R. Mohs,et al.  A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease , 1998, Neurology.

[10]  K. Shulman,et al.  Factors determining the decision to institutionalize dementing individuals: a prospective study. , 1993, The Gerontologist.

[11]  L. Schneider,et al.  Long-term tacrine (Cognex) treatment , 1996, Neurology.

[12]  H. Feldman,et al.  A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer’s disease , 2001, Neurology.

[13]  M. Lieberman,et al.  Factors affecting decisions to institutionalize demented elderly. , 1991, The Gerontologist.

[14]  Dirk Deleu,et al.  A 1-year, randomized, placebo-controlled study of donepezil in patients with mild to moderate AD. , 2001, Neurology.

[15]  R. Mohs,et al.  Donepezil improves cognition and global function in Alzheimer disease: a 15-week, double-blind, placebo-controlled study. Donepezil Study Group. , 1998, Archives of internal medicine.

[16]  R. Mohs,et al.  A 1-year, placebo-controlled preservation of function survival study of donepezil in AD patients , 2001, Neurology.

[17]  G A Chase,et al.  Psychiatric symptoms and nursing home placement of patients with Alzheimer's disease. , 1990, The American journal of psychiatry.

[18]  P J Neumann,et al.  Alzheimer's disease care: costs and potential savings. , 1998, Health affairs.

[19]  S. Deinard,et al.  Longitudinal Study of Death and Institutionalization in Patients with Primary Degenerative Dementia , 1988, Journal of the American Geriatrics Society.

[20]  R. S. Doody, MD, PhD,et al.  Practice parameter: Management of dementia (an evidence-based review): Report of the Quality Standards Subcommittee of the American Academy of Neurology , 2001 .

[21]  L. Teri,et al.  Behavior and caregiver burden: behavioral problems in patients with Alzheimer disease and its association with caregiver distress. , 1997, Alzheimer disease and associated disorders.

[22]  K. Lapane,et al.  Tacrine Therapy is Associated with Reduced Mortality in Nursing Home Residents with Dementia , 2002, Journal of the American Geriatrics Society.

[23]  S H Ferris,et al.  A family intervention to delay nursing home placement of patients with Alzheimer disease. A randomized controlled trial. , 1996, JAMA.

[24]  T Hope,et al.  Predictors of institutionalization for people with dementia living at home with a carer , 1998, International journal of geriatric psychiatry.

[25]  B. Winblad,et al.  Assessing the societal impact of acetylcholinesterase inhibitor therapies. , 1999, Alzheimer Disease and Associated Disorders.

[26]  C. Pieper,et al.  Predictors of time to institutionalization of patients with Alzheimer's disease , 1997, Neurology.

[27]  D. Asch,et al.  Caregivers’ preferences for the treatment of patients with Alzheimer’s disease , 2000, Neurology.

[28]  B. Gordon,et al.  Open-label, multicenter, phase 3 extension study of the safety and efficacy of donepezil in patients with Alzheimer disease. , 2001, Archives of neurology.

[29]  R. Doody,et al.  Long-term efficacy and safety of donepezil in the treatment of Alzheimer’s disease: final analysis of a US multicentre open-label study , 2000, European Neuropsychopharmacology.

[30]  Marco Trabucchi,et al.  An Economic Perspective on Alzheimer's Disease , 1999, Journal of geriatric psychiatry and neurology.

[31]  E. Tangalos,et al.  Patterns and Predictors of Institutionalization in Community‐Based Dementia Patients , 1994, Journal of the American Geriatrics Society.